Hannon Jason 4

What Happened

• Jason Hannon, a director of Orthofix Medical Inc. (OFIX), received an award of 14,965 deferred stock units on 2026-06-10. The units were granted at $0.00 (no cash paid). Each deferred stock unit represents a contingent right to one share of common stock and will vest in full on the first anniversary of the grant date, subject to Hannon's continued service.

Key Details

• Transaction date: 2026-06-10; filing date: 2026-06-12 (Form 4).
• Grant type: Award/Acquisition (code A); price reported $0.00.
• Vesting: Units vest in full on the first anniversary of the grant (per footnote F1). Vested units convert to common stock and will be settled within 45 days of the reporting person's termination of service.
• Shares owned after transaction: approximately 80,699 total securities (14,965 newly granted deferred stock units plus 63,631 previously reported deferred stock units and 2,103 shares acquired under Orthofix’s Stock Purchase Plan, per footnote F2).
• Footnote F2 notes the SPP share acquisitions (10/31/2025 and 4/30/2026) are exempt from Section 16(b) under Rule 16b-3(b)(5).
• Filing appears timely (Form 4 filed two days after the transaction).

Context

• This was a grant of deferred stock units (a compensation award), not an open-market purchase or sale; the award conveys a contingent right to future shares rather than immediate free-trading stock. Such awards are routine director compensation and do not, by themselves, indicate buying or selling sentiment.